Martin P, Dubois, et al. Gut. 2014 Nov 26, doi: 10.1136/gutjnl-2014-308041 – Download the article Publication
Catégorie : 2014
TG4010 Immunotherapy Combined with First-line Therapy in Advanced Non- Small Cell Lung Cancer (NSCLC). Phase 2b Results of the TIME Study
Elisabeth Quoix, et al. Journal for Immunotherapy of Cancer, 2014, 2 (suppl. 3), O12 – Download the article Publication
Rapport financier trimestriel au 30 septembre 2014
266_fr
TIME: A Phase 2b/3 Evaluating TG4010 in Combination with First-line Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC). Phase 2b results.
ESMO 2014-Poster TG4010 TIME Ph 2b Elisabeth Quoix, et al. ESMO 2014 Congress, Madrid, Spain, 26-30 September 2014, Abst. 5152 Download the poster here Poster Presentation
Rapport financier du premier semestre 2014 et informations sur TG4010
261_fr
Efficacy of immunotherapy with TG4040, Peg-interferon, and ribavirin in A phase 2 study of patients with chronic HCV infection.
Adrian Di Bisceglie, et al. Gastroenterology, 2014; Mar 18 – Download the article Publication
Comparative analysis of immunization schedules using a novel adenovirus – based immunotherapeutic targeting hepatitis B in naïve and tolerant mouse models.
Houda Boukhebza, et al. Vaccine. 2014, 32(26):3256-63. – Download the article Publication
Transgene publie son rapport financier trimestriel au 31 mars 2014
254_fr
Combination of the oncolytic vaccinia virus TG6002 with conventional chemotherapeutic agents in human tumor models resistant to viral oncolysis.
Johann Foloppe, et al. 8th International Conference on Oncolytic Virus Therapeutics. 10-13 April 2014, Oxford, United Kingdom, Abst. 64 Download the poster here Poster Presentation
Transgene : résultats annuels 2013 et point sur l’avancée des produits
253_fr
